Skip to main content

2022 CTOS Annual Meeting Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Ingrid Mintautas, B.A

Associate Director, Clinical Operations
C4 Therapeutics

Poster(s):

(P 312) A PHASE 1/2 STUDY OF CFT8634, A NOVEL BIFUNCTIONAL DEGRADATION ACTIVATING COMPOUND (BIDAC) DEGRADER OF BRD9, IN SYNOVIAL SARCOMA AND SMARCB1-NULL TUMORS